Integrating Immune Checkpoint Inhibitors and Targeted Therapies in the Treatment of Early Stage Non-small Cell Lung Cancer: a Narrative Review

Overview

Journal Transl Lung Cancer Res

Date 2021 Jan 25

PMID 33489825

Citations 9

Authors

Ana Ortega-Franco

Virginia Calvo

Fabio Franco

Mariano Provencio

Raffaele Califano

Affiliations

Soon will be listed here.

Abstract

Prognosis of early stage non-small cell lung cancer (eNSCLC) is poor even when treated radically with surgery and (neo)adjuvant chemotherapy (Cht). The discovery of tyrosine kinase inhibitors (TKIs) for oncogene addicted NSCLC and immune checkpoint inhibitors (ICIs) have revolutionised the therapeutic paradigm and improved survival of advanced NSCLC. The unprecedented impact of these drugs has shifted the focus of investigation to early stage disease aiming at improving cure. In this context, several single arm phase II studies evaluating neoadjuvant ICI alone or in combination with platinum-based Cht have shown encouraging rates of pathological response which have spurred several ongoing randomized trials with (neo)adjuvant ICI. More recently, ADAURA study evaluating adjuvant osimertinib demonstrated a profound reduction of the risk of recurrence in patients with stage I (>4 cm)-IIIA eNSCLC harbouring EGFR sensitizing mutations. ICIs and TKIs represent a true revolution in the treatment of eNSCLC call to challenge the current standard of care. However, questions regarding drug resistance, recurrence patterns, biomarker identification, optimal treatment duration and sequencing need be answered to effectively integrate new drugs in the rapidly evolving therapeutic landscape of NSCLC. In this review we critically review new developments and future perspectives of TKIs and ICI as (neo)adjuvant strategies for eNSCLC.

Citing Articles

Perioperative immunotherapy in stage IB-III non-small cell lung cancer: a critical review of its rationale and considerations.

Sim J, Choi J, Yong Lee S Korean J Intern Med. 2023; 38(6):787-796.

PMID: 37939663 PMC: 10636541. DOI: 10.3904/kjim.2023.345.

Clinical applications of DNA methylation profiling in lung cancer.

Castro-Gonzalez S, Cuadros M, Medina P Transl Lung Cancer Res. 2023; 12(6):1342-1345.

PMID: 37425406 PMC: 10326779. DOI: 10.21037/tlcr-23-95.

Fracture rate increases after immune checkpoint inhibitor treatment: a potential new immune related adverse event.

Ye C, Lee K, Leslie W, Lin M, Walker J, Kolinsky M Osteoporos Int. 2023; 34(4):735-740.

PMID: 36729143 DOI: 10.1007/s00198-023-06690-1.

Augmenting Granzyme B-Expressing NK Cells by Invariant NKT Ligand-Loaded APCs in Patients with Postoperative Early Stage Non-Small Cell Lung Cancer: Results of a Randomized Phase II Study.

Iyoda T, Shimizu K, Kawamura M, Shinga J, Watanabe T, Fukunaga K Immunohorizons. 2023; 7(1):1-16.

PMID: 36637516 PMC: 10563390. DOI: 10.4049/immunohorizons.2200091.

A cuproptosis-related long non-coding RNA signature to predict the prognosis and immune microenvironment characterization for lung adenocarcinoma.

Ma S, Zhu J, Wang M, Zhu J, Wang W, Xiong Y Transl Lung Cancer Res. 2022; 11(10):2079-2093.

PMID: 36386454 PMC: 9641048. DOI: 10.21037/tlcr-22-660.

References

Antonia S, Villegas A, Daniel D, Vicente D, Murakami S, Hui R . Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. N Engl J Med. 2017; 377(20):1919-1929. DOI: 10.1056/NEJMoa1709937. View

Albain K, Swann R, Rusch V, Turrisi 3rd A, Shepherd F, Smith C . Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial. Lancet. 2009; 374(9687):379-86. PMC: 4407808. DOI: 10.1016/S0140-6736(09)60737-6. View

Soria J, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, Lee K . Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer. N Engl J Med. 2017; 378(2):113-125. DOI: 10.1056/NEJMoa1713137. View

Rittmeyer A, Barlesi F, Waterkamp D, Park K, Ciardiello F, von Pawel J . Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet. 2016; 389(10066):255-265. PMC: 6886121. DOI: 10.1016/S0140-6736(16)32517-X. View

Eggermont A, Chiarion-Sileni V, Grob J, Dummer R, Wolchok J, Schmidt H . Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy. N Engl J Med. 2016; 375(19):1845-1855. PMC: 5648545. DOI: 10.1056/NEJMoa1611299. View

Paik J, Choi C, Kim H, Jang S, Choe G, Kim D . Clinicopathologic implication of ALK rearrangement in surgically resected lung cancer: a proposal of diagnostic algorithm for ALK-rearranged adenocarcinoma. Lung Cancer. 2011; 76(3):403-9. DOI: 10.1016/j.lungcan.2011.11.008. View

Zhong W, Wang Q, Mao W, Xu S, Wu L, Shen Y . Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1-N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study. Lancet Oncol. 2017; 19(1):139-148. DOI: 10.1016/S1470-2045(17)30729-5. View

Depierre A, Milleron B, Moro-Sibilot D, Chevret S, Quoix E, Lebeau B . Preoperative chemotherapy followed by surgery compared with primary surgery in resectable stage I (except T1N0), II, and IIIa non-small-cell lung cancer. J Clin Oncol. 2002; 20(1):247-53. DOI: 10.1200/JCO.2002.20.1.247. View

Brahmer J, Reckamp K, Baas P, Crino L, Eberhardt W, Poddubskaya E . Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. N Engl J Med. 2015; 373(2):123-35. PMC: 4681400. DOI: 10.1056/NEJMoa1504627. View

10.

Pennell N, Neal J, Chaft J, Azzoli C, Janne P, Govindan R . SELECT: A Phase II Trial of Adjuvant Erlotinib in Patients With Resected Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer. J Clin Oncol. 2018; 37(2):97-104. PMC: 6524649. DOI: 10.1200/JCO.18.00131. View

11.

Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E . Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012; 13(3):239-46. DOI: 10.1016/S1470-2045(11)70393-X. View

12.

Rizvi N, Rusch V, Pao W, Chaft J, Ladanyi M, Miller V . Molecular characteristics predict clinical outcomes: prospective trial correlating response to the EGFR tyrosine kinase inhibitor gefitinib with the presence of sensitizing mutations in the tyrosine binding domain of the EGFR gene. Clin Cancer Res. 2011; 17(10):3500-6. PMC: 3261615. DOI: 10.1158/1078-0432.CCR-10-2102. View

13.

Mouillet G, Monnet E, Milleron B, Puyraveau M, Quoix E, David P . Pathologic complete response to preoperative chemotherapy predicts cure in early-stage non-small-cell lung cancer: combined analysis of two IFCT randomized trials. J Thorac Oncol. 2012; 7(5):841-9. DOI: 10.1097/JTO.0b013e31824c7d92. View

14.

Li N, Ou W, Ye X, Sun H, Zhang L, Fang Q . Pemetrexed-carboplatin adjuvant chemotherapy with or without gefitinib in resected stage IIIA-N2 non-small cell lung cancer harbouring EGFR mutations: a randomized, phase II study. Ann Surg Oncol. 2014; 21(6):2091-6. DOI: 10.1245/s10434-014-3586-9. View

15.

Socinski M, Jotte R, Cappuzzo F, Orlandi F, Stroyakovskiy D, Nogami N . Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC. N Engl J Med. 2018; 378(24):2288-2301. DOI: 10.1056/NEJMoa1716948. View

16.

Liu J, Blake S, Yong M, Harjunpaa H, Ngiow S, Takeda K . Improved Efficacy of Neoadjuvant Compared to Adjuvant Immunotherapy to Eradicate Metastatic Disease. Cancer Discov. 2016; 6(12):1382-1399. DOI: 10.1158/2159-8290.CD-16-0577. View

17.

Kelly K, Chansky K, Gaspar L, Albain K, Jett J, Ung Y . Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023. J Clin Oncol. 2008; 26(15):2450-6. DOI: 10.1200/JCO.2007.14.4824. View

18.

Cortes A, Urquizu L, Hernando Cubero J . Adjuvant chemotherapy in non-small cell lung cancer: state-of-the-art. Transl Lung Cancer Res. 2015; 4(2):191-7. PMC: 4384209. DOI: 10.3978/j.issn.2218-6751.2014.06.01. View

19.

Chaft J, Oxnard G, Sima C, Kris M, Miller V, Riely G . Disease flare after tyrosine kinase inhibitor discontinuation in patients with EGFR-mutant lung cancer and acquired resistance to erlotinib or gefitinib: implications for clinical trial design. Clin Cancer Res. 2011; 17(19):6298-303. PMC: 3756539. DOI: 10.1158/1078-0432.CCR-11-1468. View

20.

Goldstraw P, Crowley J, Chansky K, Giroux D, Groome P, Rami-Porta R . The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J Thorac Oncol. 2007; 2(8):706-14. DOI: 10.1097/JTO.0b013e31812f3c1a. View